Welcome to our dedicated page for COPRF news (Ticker: COPRF), a resource for investors and traders seeking the latest updates and insights on COPRF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect COPRF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of COPRF's position in the market.
Medivolve Inc. (OTC:COPRF) announces its subsidiary, Collection Sites, LLC, will provide free COVID-19 PCR tests to uninsured and undocumented patients through a government-funded HRSA program. Collection Sites will charge a fee per test while receiving $75-100 reimbursement from the program. The initiative begins in California, offering 24-hour results. The arrangement with Transplant Genomics supports high-complexity lab testing. Medivolve aims to enhance access to medical services as part of its strategy to tackle COVID-19.
Medivolve Inc. (OTC:COPRF) is enhancing its position in the COVID-19 health sector by launching a nationwide network for rapid COVID testing and plans for telehealth services. The company's strategy includes developing mobile clinics and leveraging its existing customer base through its subsidiary, Collection Sites. These initiatives aim to transform healthcare post-pandemic, focusing on prevention, detection, and treatment. Medivolve is poised to benefit from trends in telehealth and testing enhancements, making significant strides in delivering healthcare innovations.
Medivolve Inc. has introduced multi-week custom testing solutions for a high school athletics department in Redlands, California, and a film production company in Los Angeles as part of its new business strategy. The company aims to expand its testing services across the U.S. Following solid sales results in February, with over 30,000 tests conducted, Medivolve CEO Doug Sommerville noted a shift towards business-focused custom testing solutions. An investor webinar is scheduled for March 23, 2021, to discuss recent developments.
Medivolve Inc. (OTC:COPRF) has signed a Letter of Intent to acquire a 100% equity stake in Modern Rx LLC, a Las Vegas-based pharmacy, enhancing its telehealth strategy. The $100,000 cash deal, supplemented by one million shares, aims to facilitate the direct filling of prescriptions for Collection Sites' telehealth patients. The acquisition is seen as crucial for expanding telehealth services as the program launches. Medivolve will host an investor webinar on March 23rd to discuss recent developments.
Medivolve Inc. (OTC:COPRF) has launched a partnership with Besser Brands in Florida, operating 9 Collection Sites. Besser Brands will manage all operational costs and pay royalties on tests sold. Additionally, Medivolve has completed the acquisition of Noble Bioscience Corp., gaining access to Nuturell’s Surface Shield technology, a COVID-19 disinfectant effective up to 90 days. This expansion positions Medivolve to enhance its COVID-19 testing capabilities amidst increasing demand.
Medivolve Inc. (OTC:COPRF) has cancelled its agreement to acquire Karland Health, LLC after due diligence showed the acquisition wouldn't be strategically beneficial. Medivolve's CEO, Doug Sommerville, emphasized that the company is still committed to its telehealth strategy, which will be elaborated on in a corporate update webinar scheduled for February 22 at 1 pm ET. Additionally, Medivolve completed a shares for debt settlement, issuing 10,958,024 common shares at $0.46 per share to settle <$5.04 million> in debt.
Medivolve Inc. (OTC:COPRF) announces an investor awareness campaign following its successful operational results, including the sale of 73,973 tests at an average price of $96 in January. To adapt to pandemic conditions, the company has shifted its marketing budget to digital efforts, partnering with Emerging Markets Consulting and Winning Media for comprehensive investor relations services. The campaign aims to enhance visibility in the telehealth market and support ongoing COVID-19 testing initiatives at its Collection Sites subsidiary.
Medivolve Inc. (OTC:COPRF) is hosting a webinar on February 22 at 1 pm ET to update investors on its telehealth strategy and recent business developments. The webinar will feature CEO Doug Sommerville and Dr. Glenn Copeland.
Additionally, Tim Shelburn, President of Collection Sites, is stepping down from his executive role but will remain as an advisor during the leadership transition. Collection Sites specializes in COVID-19 testing, providing rapid antibody and antigen tests.
Medivolve Inc. has signed a binding letter of intent to acquire Karland Health, LLC, aiming to enhance its healthcare service offerings. The transaction involves issuing 20 million common shares in exchange for a 100% stake. Additionally, Medivolve will settle $5,040,691 of its debts through the issuance of approximately 10.96 million shares at $0.46 each. This acquisition will allow Medivolve to integrate telehealth services and expand its COVID-19 testing capabilities, further emphasizing its commitment to accessible healthcare.
FAQ
What is the market cap of COPRF (COPRF)?
